
ERS Genomics and Sai Life Sciences Sign CRISPR/Cas9 License Agreement to Advance Precision Genome Editing in Drug Discovery and Development
<a href="https://news.google.com/rss/articles/CBMinwJBVV95cUxPU3g1Wm92WnkzMTl6b2xrQ3BFVDVKZjhtQ0dqYlYwTU1fZUdneTczQkxmWWxMRTdwLVVVQXY4N3M4aHJWa2lHa0gxaVI2Uk9CdkplbWU1WXhqT2x2ak5PUTNwai1hbC12QUhrQlp3cE13NVBZUVRTT29GZnlJRXZHQVpNLUQxZmppS1p5aDZSRDJlNnY5UmFwTUFiUjJna0JkSG82SWszVF9EWmUtaWxjOVhFa1Q1OEwwVHJzcEs4b016WGhuZWduYk5WbWlmbDhoSDFQMVlwY2hVUlhNMUFPTlVDeHktV1ZSdjdJZWtJQ2NtbURsM0ZhU2Ztbmd6eUhwMjlEX3ZBX0ZrZlFIaHotWDloM0hWSW9XUDZlUzhVdw?oc=5" target="_blank">ERS Genomics and Sai Life Sciences Sign CRISPR/Cas9 License Agreement to Advance Precision Genome Editing in Drug Discovery and Development</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>

